Table 3.
Effects of exercise intervention on secondary outcomes (engraftment kinetics).
| Allogeneic-HSCT | ||||||
|
Control Group
(n = 39) |
Exercise Group
(n = 47) |
|||||
| Outcome | Unadjusted | Adjusted * | Unadjusted | Adjusted * |
Unadjusted between-group Difference
p- Value |
Adjusted * between-group Difference
p-Value |
| Time to neutrophil engraftment (days) |
16 ± 1 (14, 17) |
15 ± 2 (11, 19) |
14 ± 1 (13, 16) |
13 ± 2 (9, 17) |
0.126 | 0.170 |
| Time to platelet count ≥ 20 × 109/L (days) |
13 ± 1 (11, 15) |
13 ± 3 (7, 19) |
12 ± 1 (10, 14) |
11 ± 3 (6, 17) |
0.368 | 0.454 |
| Time to platelet count ≥ 50 × 109/L (days) |
15 ± 1 (12, 18) |
21 ± 4 (13, 29) |
14 ± 1 (12, 17) |
19 ± 4 (11, 27) |
0.857 | 0.489 |
| Time to platelet count ≥ 100 × 109/L (days) |
19 ± 3 (14, 25) |
73 ± 8 (56, 89) |
22 ± 2 (17, 27) |
73 ± 7 (58, 88) |
0.382 | 0.960 |
| Myelosuppression (days) |
12 ± 1 (10, 14) |
11 ± 3 (4, 17) |
10 ± 1 (8, 12) |
9 ± 3 (3, 16) |
0.329 | 0.563 |
| Autologous-HSCT | ||||||
|
Control Group
(n = 14) |
Exercise Group
(n = 18) |
|||||
| Unadjusted | Adjusted ** | Unadjusted | Adjusted ** |
Unadjusted between-Group Difference
p-Value |
Adjusted ** between-Group Difference
p-Value |
|
| Time to neutrophil engraftment (days) |
13 ± 1 (12, 14) |
13 ± 1 (12, 14) |
12 ± 0 (11, 13) |
13 ± 1 (12, 14) |
0.403 | 0.920 |
| Time to platelet count ≥ 20 × 109/L (days) |
10 ± 1 (8, 13) |
10 ± 2 (7, 14) |
12 ± 1 (11, 13) |
13 ± 1 (10, 16) |
0.251 | 0.282 |
| Time to platelet count ≥ 50 × 109/L (days) |
13 ± 1 (10, 17) |
12 ± 1 (7, 18) |
15 ± 1 (12, 17) |
16 ± 1 (11, 20) |
0.460 | 0.195 |
| Time to platelet count ≥ 100 × 109/L (days) |
16 ± 4 (15, 19) |
N/A | 19 ± 3 (16, 21) |
N/A | 0.667 | N/A |
| Myelosuppression (days) |
7 ± 1 (6, 8) |
7 ± 1 (5, 8) |
8 ± 1 (7, 9) |
9 ± 1 (7, 10) |
0.135 | 0.071 |
All data are expressed as mean ± SEM (95% confidence interval). We corrected all the analyses for multiple comparisons with the Bonferroni method; that is, dividing 0.05 by the number of comparisons. Thus, the threshold p-value for statistical significance was set at 0.01 (=0.05/5) for both allogeneic and autologous HSCT. Abbreviations: HSCT, hematopoietic stem cell transplantation; N/A, not available. Symbol: * adjusted by group (i.e., exercise or control), graft manipulation (i.e., manipulated or unmanipulated), age at hematopoietic stem cell transplantation, sex differences between donor and recipient (i.e., yes or no), conditioning regimen (i.e., myeloablative or nonmyeloablative), source (i.e., peripheral blood or umbilical cord) and origin (i.e., parent, sibling or unrelated donor) of donor cells, graft-versus-host-disease prophylaxis (i.e., cyclosporine or cyclosporine + methylprednisolone), disease status (i.e., 1st, 2nd, >2nd complete remission or not in remission) and human leukocyte antigens match status (i.e., HLA-matched and related, HLA-matched and unrelated, or HLA-mismatched (related or unrelated)); ** adjusted by group, age at HSCT, conditioning regimen, source of donor cells and disease status (those mentioned above for allo-HSCT).